For the quarter ending 2025-10-31, ODYY had $6,502 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-10-31 | 2025-07-31 |
|---|---|---|
| Net loss and comprehensive loss | -483,447 | -1,742,691 |
| Amortization | - | 0 |
| Stock-based compensation | 0 | 108,399 |
| Financing costs | 507,368 | - |
| Allowance for research and development rebate due | 0 | - |
| Gain on sale of product candidates and related assets | - | 0 |
| Allowance for research and development rebate due from australian government | - | 22,625 |
| Change in fair value of derivative liability | 422,419 | - |
| Impairment of investment in preferred stock of oragenics, inc | - | 0 |
| Amortization of debt discount and closing costs | 39,601 | 50,965 |
| Loss from change in fair value of oragenics, inc. common stock | 0 | -459,417 |
| Financing costs paid with issuance of common stock | 1,750 | 0 |
| Increase in prepaid expenses and other current assets | 87,397 | -6,990 |
| Decrease in research and development rebate due from australian government | - | 0 |
| Increase in accounts payable and accrued wages | 73,285 | 228,379 |
| Increase in accounts payable and accrued wages, officers | 32,308 | 320,838 |
| Increase in accrued interest | 54,953 | 197,686 |
| Net cash used in operating activities | -283,998 | -347,392 |
| Cash proceeds from sale of assets | - | 0 |
| Cash proceeds from sale of oragenics, inc. common stock, net of commission and fees | - | 69,787 |
| Net cash provided by investing activities | - | 69,787 |
| Net proceeds from notes payable | 290,500 | 300,000 |
| Principal payments made on notes payable | - | 0 |
| Proceeds from equity financing | - | 0 |
| Deferred closing costs | - | 5,690 |
| Net cash provided by financing activities | 290,500 | 294,310 |
| Net increase in cash and cash equivalents | 6,502 | 16,705 |
| Cash and cash equivalents at beginning of period | 19,084 | 2,379 |
| Cash and cash equivalents at end of period | 25,586 | 19,084 |
Odyssey Health, Inc. (ODYY)
Odyssey Health, Inc. (ODYY)